

2 August 2023

LEI: 213800RG7JNX7K8F7525



Life Science REIT plc
("Life Science REIT" or the "Company")

Notice of Half Year Results

Life Science REIT (LSE: LABS), the real estate investment trust focused on UK life science properties, is pleased to announce that it will report its interim results for the six months ended 30 June 2023 on Thursday 21 September 2023.

A presentation for analysts will be held at 9.30am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. The presentation will be hosted by Ironstone Asset Management, the Company's Investment Adviser.

Analysts who wish to attend the presentation, please RSVP to lifesciencereit@buchanan.uk.com

Following the presentation, a recording will be made available at the Company's website, <https://lifesciencereit.co.uk>

FOR FURTHER INFORMATION, PLEASE CONTACT:

Ironstone Asset Management - Investment Adviser +44 20 3011 2160

Simon Farnsworth
Joanna Waddingham, Head of Investor Relations and Corporate Affairs
Joanna.Waddingham@ironstoneam.com

Link Company Matters Limited - Company Secretary
labs_cosec@linkgroup.co.uk

Panmure Gordon (UK) Limited - Joint Corporate Broker +44 20 7886 2500
Alex Collins / Tom Scrivens

Jefferies International Limited - Joint Corporate Broker +44 20 7029 8000
Tom Yeadon / Andrew Morris / Oliver Nott / Harry Randall

G10 Capital Limited - AIFM +44 20 7397 5450
Maria Baldwin

Buchanan - Financial PR +44 20 7466 5000
Mark Court / Henry Wilson / Verity Parker
LifeSciencereit@buchanan.uk.com

Notes to editors

Life Science REIT is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.

Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is benefiting from sustained growth and demand for laboratory space.

The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.

The Company's investment policy is focused on capital growth whilst also providing a growing level of income.

Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.

Further information is available at <https://lifesciencereit.co.uk>. To sign up for email alerts, please visit <https://lifesciencereit.co.uk/investors/>.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORFFEITLIV